Department of Pediatrics
-
July 24, 2024
Monroe Carell Jr. Children’s Hospital at Vanderbilt adds pancreas and lung transplant services
Recognized as a major regional referral center for heart, kidney and liver transplantation, incorporating pancreas and lung transplant services for pediatric patients bolsters the well-established expertise currently offered by the Vanderbilt Transplant Center. -
July 22, 2024
Opioid treatment can avoid foster care placement: study
If women are given medications to treat opioid use disorder during their pregnancy they are significantly more likely to retain custody of their newborns after delivery -
July 12, 2024
Anthony Flores named director of the Division of Pediatric Infectious Diseases
In his clinical and research work, Flores examines the mechanisms by which bacterial pathogens cause disease in humans. -
July 8, 2024
Noted pediatric endocrinologist Jennifer Najjar retires after 47 years at Vanderbilt
After 47 years as a pediatric endocrinologist at Vanderbilt University Medical Center and Monroe Carell Jr. Children’s Hospital at Vanderbilt, Jennifer Najjar is reflecting on her life of work, highlighting moments of pride and gratitude for her patients and colleagues, and relishing in her ability to practice medicine while also training the next generation of pediatric doctors. -
July 1, 2024
Vanderbilt mourns the loss of neonatal medicine pioneer Mildred Stahlman
Mildred T. Stahlman, MD, who pioneered the treatment of lung disease in premature infants and who was a tireless advocate of children of all ages, died June 29. She was 101. -
June 28, 2024
Antibody trial launched to address enterovirus threat
Enterovirus D68 has caused an increasing number of infections during the past decade and is associated with acute flaccid myelitis, a polio-like condition that mostly affects children and causes sudden weakness and paralysis. -
June 25, 2024
International trial introduces another curative option for sickle cell disease
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.